Cambridge Investment Research Advisors
RVNC

Cambridge Investment Research Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,981
Closed -$225K – 3315
2023
Q1 		$225K Buy
+6,981
New +$218K ﹤0.01% 2731

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors's RVNC Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 6,981 shares — an estimated $225K sold.

Cambridge Investment Research Advisors first reported a position in RVNC in Q1 2023 and held it in 1 quarter. The position peaked at $225K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Cambridge Investment Research Advisors reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,981 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $225K.
  • Cambridge Investment Research Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Revance Therapeutics, Inc. position peaked at $225K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.